2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, Neutropenia, Infectious Diseases, Viral, Bacterial, Fungal, Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant, Young Adult
PAPER

6235 Association between fatigue and hemoglobin levels in patients with warm autoimmune hemolytic anemia: Results from a real-world survey

Irina Murakhovskaya, MD, Louis Jackson, PharmD2, Jacqueline Pesa, MSEd, PhD, MPH3, Stephen Fortin4, Susanna Libby5, Kieran Wynne-Cattanach, MSc6, Katherine Smethers, MSci7, Emily Quinones8, Surbhi Shah, MBBS, MD9
1 Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, United States
2 Johnson & Johnson, Horsham, Pennsylvania, United States
3 Johnson & Johnson, Horsham, Pennsylvania, United States
4 Johnson & Johnson, Horsham, Pennsylvania, United States
5 Adelphi Real World, Bollington, United Kingdom
6 Adelphi Real World, Bollington, United Kingdom
7 Adelphi Real World, Bollington, United Kingdom
8 Adelphi Real World, Bollington, United Kingdom
9 Mayo Clinic Hematology & Oncology, Phoenix, Arizona, United States

Background:

Warm autoimmune hemolytic anemia (wAIHA) is a rare, life-threatening disease characterized by IgG autoantibody-mediated premature destruction of erythrocytes. Limited real-world data exists on the relationship between anemia and fatigue severity in wAIHA patients. The current study assessed the association between fatigue and hemoglobin levels in wAIHA patients.

Methods:

Data were drawn from the Adelphi wAIHA I Disease Specific Programme™, a cross-sectional survey with elements of retrospective data collection of physicians and their patients with wAIHA conducted in the United States of America between February 2025 and October 2025. Physicians completed forms for up to their next 10 consecutively consulting patients with wAIHA capturing demographics, and clinical characteristics such as hemoglobin levels, anemia and fatigue. In addition, physicians completed identical forms for a subset of patients who had received at least one rituximab cycle. Patients voluntarily completed a form which included the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue). Using the FACIT-Fatigue scores, fatigue was classified as none or minimal (>40), mild (>30 to ≤40), moderate (>21 to ≤30), or severe (≤21). Severity of anemia was classified by hemoglobin level as none (>12 g/dL), mild (10-11.9 g/dL), moderate (8.0-9.9 g/dL) or severe (<8.0 g/dL). Normative values of general population-based studies report mean (SD) FACIT-Fatigue scores of 43.5 (8.3) (Montan et al.). Bivariate and correlation analysis were used to assess the association between FACIT-Fatigue scores, hemoglobin levels and physician-reported anemia.

Results:

Overall, 7 physicians provided data for 67 patients who also completed the self-reported questionnaire. Among these patients, 82.1% of patients were diagnosed with primary wAIHA, 53.7% were male, and 73.1% were White. The mean (standard deviation [SD]) patient age was 40.1 (12.3) years, body mass index was 26.2 (3.6) kg/m2, and time since diagnosis was 15.4 (18.4) months.  Patients had received a mean (SD) of 1.2 (0.5) treatment lines, with 89.6% of patients on treatment at survey. Treatment was initiated a mean (SD) of 261.1 (352.5) days prior to survey.

Physician reported median (IQR) hemoglobin levels at the time of survey were 8.4 (8.0-10.4 g/dL, with 19.4%, 13.4%, 52.2% and 14.9% patients experiencing no, mild, moderate, and severe anemia, respectively. Overall, 72.7% of patients were reported to have a hemoglobin value <10 g/dL at their most recent test. Additionally, physicians reported 17.9%, 43.3%, 35.8% and 3.0% of patients had no, mild, moderate, and severe fatigue, respectively.

Patients reported mean (SD) FACIT-Fatigue scores of 36.0 (12.4), with 46.3% of patients experiencing no fatigue, 17.9% mild fatigue, 17.9% moderate fatigue and 17.9% severe fatigue at the time of survey. Patients with lower hemoglobin levels reported substantially greater fatigue; there was a statistically significant positive association between FACIT Fatigue scores and physician-reported total hemoglobin levels (r=0.4576, p=0.0011), representing a 4.89 decrease in FACIT-Fatigue score for every 1g/dL decrease in hemoglobin level.

The median (IQR) FACIT-Fatigue score of patients stratified by severity of anemia was as follows: no anemia, 51.0 (44.5-52.0); mild anemia, 27.0 (20.5-33.0); moderate anemia, 41.0 (35.0-44.0); and severe anemia, 21.0 (19.3-24.8). A statistically significant difference was observed between FACIT-Fatigue scores and anemia severity strata (p<0.0001). Additionally, there was a statistically significant difference between FACIT-Fatigue scores reported by patients and physician-reported (none, mild, moderate and severe) fatigue (p<0.0001). The median (IQR) FACIT-Fatigue score of patients by physician-reported fatigue strata was as follows: no fatigue, 52.0 (51.0-52.0); mild fatigue, 38.0 (30.0-43.0); moderate fatigue, 27.0 (20.3-39.8); and severe fatigue, 16.0 (8.0-24.0).

Conclusion:

Our results show that more severe anemia was associated with greater fatigue, as evidenced by positive associations between hemoglobin levels, physician-reported anemia severity, and fatigue. These findings also suggest that physicians may underestimate the level of fatigue experienced by patients. Further research is required to better understand the relationship between hemoglobin levels and patient-experienced fatigue.

Louis Jackson, PharmD: Johnson & Johnson - Stock (publicly traded); Johnson & Johnson - Current Employment